Workflow
Biogen Inc. (BIIB) Q1 Earnings Lag Estimates
BIIBBiogen(BIIB) ZACKS·2025-05-01 13:05

Core Insights - Biogen Inc. reported quarterly earnings of 3.02pershare,missingtheZacksConsensusEstimateof3.02 per share, missing the Zacks Consensus Estimate of 3.26 per share, and down from 3.67pershareayearago,representinganearningssurpriseof−7.363.67 per share a year ago, representing an earnings surprise of -7.36% [1] - The company posted revenues of 2.43 billion for the quarter, exceeding the Zacks Consensus Estimate by 8.91%, and up from 2.29billionyear−over−year[2]−Biogenshareshavedeclinedapproximately20.82.29 billion year-over-year [2] - Biogen shares have declined approximately 20.8% since the beginning of the year, compared to a decline of -5.3% for the S&P 500 [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is 4.10 on revenues of 2.33billion,andforthecurrentfiscalyear,itis2.33 billion, and for the current fiscal year, it is 15.63 on revenues of 9.17billion[7]−TheestimaterevisionstrendforBiogenismixed,resultinginaZacksRank3(Hold),indicatingexpectedperformanceinlinewiththemarket[6]IndustryContext−TheMedical−BiomedicalandGeneticsindustry,towhichBiogenbelongs,iscurrentlyinthetop329.17 billion [7] - The estimate revisions trend for Biogen is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Biogen belongs, is currently in the top 32% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Another company in the same industry, Puma Biotech, is expected to report quarterly earnings of 0.02 per share, reflecting a year-over-year change of +140%, with revenues anticipated at $43.96 million, up 0.4% from the previous year [9][10]